Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
'We're looking forward to presenting the latest findings across our oncology portfolio at this year's congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types.'
Details on the abstracts accepted for oral presentation at ESMO include:
INCB161734 (KRAS G12D)
Preliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors
(Session Title: Proffered paper session: Developmental therapeutics. [October 19, 8:45 – 10:15 a.m. ET [2:45 – 4:15 p.m. CEST]. Abstract #916O.)
INCA33890 (PD-1/TGF β R2)
A Phase 1 Study Of INCA33890, A PD-1/Tgfβr2 Bispecific Antibody, For Advanced Solid Tumours
(Session Title: Mini oral session: Investigational immunotherapy. [October 17, 8:00 – 9:30 a.m. ET [2:00 – 3:30 p.m. CEST]. Abstract #1522.)
INCAGN2385 (LAG-3)
Retifanlimab (Anti–PD-1 Mab) Alone Or In Combination With Anti-LAG3 ± Anti-TIM3 Mabs In Previously Untreated, Recurrent And/Or Metastatic (R/M) PD-L1+ HNSCC: A Double-Blind Randomised Controlled Phase 2 Trial
(Session Title: Mini oral session: Head and neck cancer. [October 19, 10:30 a.m. – 12:00 p.m. ET [4:30 – 6:00 p.m. CEST]. Abstract #1325.)
All regular abstracts accepted for presentation at the ESMO Congress 2025 will be published online via the ESMO website on Monday, October 13 at 6:05 p.m. ET (12:05 a.m. CEST). All accepted abstracts will be published online in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
More information regarding the 2025 ESMO Congress can be found at: https://www.esmo.org/meeting-calendar/esmo-congress-2025.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte's clinical development pipeline, the potential offered by INCA33890 and INCB161734, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte's goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-K for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Why Is Sotera Health Company (SHC) Stock Soaring Today
What Happened? Shares of healthcare services company Sotera Health (NASDAQ:) jumped 20% in the morning session after the company reported strong second-quarter 2025 results that surpassed analyst expectations and raised its full-year financial outlook. The healthcare sterilization and lab testing provider announced second-quarter adjusted earnings per share of $0.20, beating analyst estimates of $0.17. Revenue for the quarter came in at $294.3 million, a 6.4% year-over-year increase, which also surpassed the consensus estimate of $275.6 million. The company's profitability also improved, with adjusted EBITDA (a measure of operational profitability) of $150.7 million, beating analyst forecasts by 9.8%. Following the strong performance, Sotera Health raised its full-year 2025 guidance, increasing its forecast for adjusted earnings per share by 7.5% to $0.78 at the midpoint. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. What Is The Market Telling Us Sotera Health Company's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for Sotera Health Company and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 18 days ago when the stock gained 3.4% amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures indicated a higher open for the markets, setting a positive tone for investors who were anticipating a heavy slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. Sotera Health Company is down 1.4% since the beginning of the year, and at $13.43 per share, it is trading 20.6% below its 52-week high of $16.91 from September 2024. Investors who bought $1,000 worth of Sotera Health Company's shares at the IPO in November 2020 would now be looking at an investment worth $534.90. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
22 minutes ago
- Yahoo
Is Super Micro Computer Stock Headed for $15 or $70 After Giant Post-Earnings Plunge?
After putting accounting controversies and Nasdaq delisting fears stemming from the delayed filings in the rearview mirror, Super Micro Computer (SMCI) had been on a strong recovery run this year. SMCI stock once again regained traction as investors bet big on its leadership in the artificial intelligence (AI) hardware space, growing demand for next-gen servers, and close partnership with chip giant Nvidia (NVDA) — all of which painted a promising growth story. But the narrative took a sharp turn in the wrong direction after the company dropped its fourth-quarter earnings report on Aug. 5. Shares of SMCI sank more than 18% in the following trading session, as Super Micro missed Wall Street's expectations on both revenue and earnings. Even guidance fell short, sparking fresh concerns about slowing growth and rising competition. More News from Barchart Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Dear Ford Stock Fans, Mark Your Calendar for August 11 Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Investor sentiment around SMCI stock has clearly taken a hit, and analysts' opinions are now deeply divided. On one end, the most bullish target on Wall Street suggests that SMCI stock could soar to $70, while on the other side, the most bearish sees it dropping all the way to $15 per share. So, with expectations stretched so far apart, can SMCI defy the doubts and reclaim its momentum? Or is there more downside still to come? About Super Micro Stock Super Micro Computer specializes in building high-powered, energy-efficient servers to support surging demand from AI, cloud services, and data centers. With operations across the U.S., Taiwan, and the Netherlands, the company has built a solid international footprint and currently holds a market capitalization of $27.8 billion. After sliding last year under the weight of negative headlines, SMCI stock came roaring back in 2025, hitting a fresh high of $66.44 in February. Even after pulling back some 32% from that peak, the stock remains up an impressive 50% so far this year, well ahead of the broader S&P 500 Index's ($SPX) modest 8.5% gain year-to-date (YTD). However, the comeback rally appears to be facing turbulence lately. SMCI is once again under pressure following its latest earnings miss, with shares tumbling 19% in just the past five trading days. A Look Inside Super Micro's Q4 Earnings Super Micro's fiscal 2025 fourth-quarter earnings report released earlier this month came as a letdown to investors, missing Wall Street's expectations on both the top and bottom lines. Revenue for the quarter rose 7.4% year-over-year (YOY) to $5.8 billion but still fell short of the $5.9 billion analysts had expected. Adjusted EPS came in at $0.41, marking a notable 24% decline from the prior year and falling below the consensus estimate of $0.44, partly because of the impact from President Donald Trump's tariffs on goods imported into the United States. While the company pointed to tariffs as a key reason for the earnings shortfall, the miss stung even more given the backdrop of soaring demand for AI infrastructure, which had set investors' expectations sky high. Instead of a blowout quarter, the results revealed mounting cost pressures and thinner margins, casting doubt on Super Micro's ability to deliver strong profits even as sales continue to rise. A key red flag was the drop in gross margin, which slipped to 9.5% from 10.2% a year ago. The decline suggests the company may be facing pricing pressure or higher costs, likely tied to competitive dynamics or more expensive AI components. As of June 30, Super Micro reported $5.2 billion in cash and equivalents, alongside $4.8 billion in total bank debt and convertible notes. Unfortunately, the disappointment didn't end at Super Micro's Q4 financials. The company's guidance for Q1 of fiscal 2026 also fell short of expectations. Management expects revenue to land between $6 billion and $7 billion, while adjusted EPS is expected to be between $0.40 and $0.52. Both of these figures miss Wall Street's forecasts for $6.6 billion in revenue and $0.59 in EPS. Over the longer term, analysts tracking Super Micro project the company's bottom line to rise 19.2% YOY to $2.05 per share in fiscal 2026, then leap 21% annually to $2.49 in fiscal 2027. What Do Analysts Think About Super Micro Stock? After the disappointing Q4 showing, several Wall Street analysts struck a more cautious tone. For instance, JPMorgan analyst Samik Chatterjee lowered the firm's price target to $45 from $46, maintaining a 'Neutral' rating. Chatterjee pointed to capital constraints and customer hesitation as key reasons the company fell short of expectations. On the other hand, Bank of America Securities analyst Ruplu Bhattacharya slightly raised the price target to $37 from $35 while sticking with an 'Underperform' rating. The analyst noted that gross margins were pressured once again, this time due to inventory reserves for older products. Bhattacharya explained that many customers are opting to wait for Nvidia's upcoming B300/GB300 GPUs, which has weighed on current demand. Overall, Wall Street sentiment on Super Micro is tilting cautious, with SMCI stock earning a consensus rating of 'Hold.' Among the 16 analysts covering the stock, opinions are clearly mixed. Only four recommend a 'Strong Buy,' while three lean toward a 'Moderate Buy.' The majority of analysts take a wait-and-see approach, with six suggesting 'Hold.' On the bearish side, one analyst has a 'Moderate Sell' rating for SMCI and two assign a 'Strong Sell' rating, reflecting growing uncertainty around the company's near-term outlook. SMCI stock has a Street-high price target of $70, indicating nearly 54% potential upside. The lowest target of $15 suggests a steep 67% drop from current levels. Key Takeaways Super Micro's wide price target range, spanning from $15 to a Street-high of $70, underscores the uncertainty surrounding its near-term trajectory. While some analysts remain bullish on its long-term AI-driven potential, others are wary of execution risks and margin pressures. With sentiment this divided, the stock's path forward may remain volatile as investors wait for more apparent signs of sustained growth. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
22 minutes ago
- Yahoo
Why Sezzle Stock Plunged Today
Key Points Sezzle delivered another round of strong growth on the top and bottom lines. Guidance calls for growth to decelerate in the second half of the year. The stock looks well priced based on its forward P/E. 10 stocks we like better than Sezzle › Shares of Sezzle (NASDAQ: SEZL) were taking a dive after better-than-expected results on the top and bottom lines were not enough to please investors. As a result, the stock was down 33.7% on the news as of 11:42 a.m. ET. Sezzle cools off Sezzle, a buy now, pay later (BNPL) company that's taken the market by storm over the last two years, continued to deliver impressive growth. Revenue grew 76.4% to $98.7 million, which beat analyst estimates at $94.9 million. Sezzle's monthly on-demand and subscribers metric reached 748,000, up from 658,000 in the previous quarter, showing solid growth in its high-frequency user base. Gross merchandise volume was also strong, up 74.2% to $927 million. Margins continued to expand as operating income jumped 116.1% to $36.1 million, and adjusted earnings per share was up 97% to $0.69. CEO Charlie Youakim said, "The product features and marketing initiative we've rolled out are driving stronger engagement and broader adoption." What's next for Sezzle While its results were strong, given its blistering growth coming into the report, investors may have expected a wider beat. Additionally, Sezzle's guidance calls for its growth to continue to decelerate as the company sees revenue growth of 60%-65% and adjusted earnings per share of $3.25, which was just slightly below the consensus at $3.26. After soaring growth through the first half of the year, that reflects a significant moderation in the second half of the year as well. Still, the stock now trades at a forward P/E of under 30, which looks like a great price for the fast-growing, disruptive BNPL player. Should you invest $1,000 in Sezzle right now? Before you buy stock in Sezzle, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Sezzle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Sezzle. The Motley Fool has a disclosure policy. Why Sezzle Stock Plunged Today was originally published by The Motley Fool Sign in to access your portfolio
